GT Biopharma (LTS:0RU9) 3-Year EBITDA Growth Rate : 68.30% (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is GT Biopharma 3-Year EBITDA Growth Rate?

GT Biopharma's EBITDA per Share for the three months ended in Mar. 2024 was €-1.51.

During the past 3 years, the average EBITDA Per Share Growth Rate was 68.30% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 68.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of GT Biopharma was 71.10% per year. The lowest was 60.80% per year. And the median was 66.80% per year.

Competitive Comparison of GT Biopharma's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, GT Biopharma's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GT Biopharma's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GT Biopharma's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where GT Biopharma's 3-Year EBITDA Growth Rate falls into.

GT Biopharma 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

GT Biopharma (LTS:0RU9) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

GT Biopharma 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of GT Biopharma's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

GT Biopharma (LTS:0RU9) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GT Biopharma Inc (LTS:0RU9) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

GTBP:USA

Address

8000 Marina Boulevard, Suite 100, Brisbane, CA, USA, 94005

Website

https://www.gtbiopharma.com

GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.

GT Biopharma (LTS:0RU9) Headlines

No Headlines